Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 3/20 | 0.75 |
| ▸ | BLM | P54132 | 3/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | APEX1 | P27695 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7148550 | 1.00 | NFKB1 (0.75) | NFKB1BLMPMP22ADRA2AADRA1A | |
| SCHEMBL15921910 | 1.00 | NFKB1 (0.75) | NFKB1BLMPMP22ADRA2AADRA1A | |
| SCHEMBL29633151 | 1.00 | NFKB1 (0.75) | NFKB1BLMPMP22ADRA2AADRA1A | |
| Hydrochloric Acid SCHEMBL8904803 | 0.98 | BLM (0.76) | NFKB1BLMPMP22ADRA2AADRA1A | |
| SCHEMBL7916052 | 0.86 | NFKB1 (0.61) | NFKB1BLMPMP22ADRA2AADRA1A | |
| Normetanephrine SCHEMBL4949341 | 0.86 | NFKB1 (1.00) | NFKB1BLMPMP22ADRA2AADRA1A | |
| Normetanephrine Hydrochloride SCHEMBL7153624 | 0.86 | NFKB1 (0.76) | NFKB1BLMPMP22ADRA2AADRA1A | |
| SCHEMBL31347553 | 0.86 | NFKB1 (0.66) | NFKB1BLMPMP22ADRA2AADRA1A | |
| Normetanephrine Hydrochloride SCHEMBL11573078 | 0.86 | NFKB1 (0.76) | NFKB1BLMPMP22ADRA2AADRA1A | |
| Normetanephrine SCHEMBL137755 | 0.86 | NFKB1 (1.00) | NFKB1BLMPMP22ADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | claimed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | claimed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250376436-A1 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | Park City Bio, LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | KULEON LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | Kuleon, LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250289817-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-12414936-B2 | Compositions comprising a serotonergic tryptamine compound | CAAMTECH, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-5079256-A | Administering to treat diseases of circulatory organs such as renal/cardiac insufficiency | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-01-07 | — | — | US | disclosed |
| US-5077406-A | Cyclization, deprotecting and salt formation | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-12-31 | — | — | US | disclosed |
| EP-0404197-A2 | Arylalkylamine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-12-27 | — | — | EP | disclosed |
| US-4966904-A | DILUROGENITAL DISORDERS; DILATION OF NEOPHROVASCULAR TRACTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-10-30 | — | — | US | disclosed |
| US-4876261-A | UROGENITAL DISORDERS; NEPHROVASCULAR DILATORS; ACT ON DOPAMINE RECEPTOR | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 1989-10-24 | — | — | US | disclosed |
| EP-0286293-A1 | Substituted tetrahydroisoquinoline compounds, their production, and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-10-12 | — | — | EP | disclosed |
| US-4340600-A | Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines | SMITHKLINE CORPORATION (US) | 1982-07-20 | — | — | US | disclosed |
| US-4186129-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, ANTICONVULSANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-01-29 | — | — | US | disclosed |
| US-3985881-A | 1(3,4,5-Trimethoxybenzamido methyl) tetrahydro isoquinoline derivatives and a process for their production | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376436-A1 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | HTR1A, HTR4, HTR5A | NFKB1 4836/4885BLM 3119/4885PMP22 3134/4885 |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | NFKB1 4863/4885BLM 2224/4885PMP22 776/4885 |
| US-20250289817-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | HTR5A, HTR1A, HTR3A | NFKB1 4758/4885BLM 3531/4885PMP22 2330/4885 |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | HTR7, HTR2C, HTR1A | NFKB1 4781/4885BLM 2600/4885PMP22 1104/4885 |
| US-12414936-B2 | Compositions comprising a serotonergic tryptamine compound | HTR3A, HTR2A, HTR5A | NFKB1 2245/4885BLM 3813/4885PMP22 1157/4885 |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | ADRA2C, ADRB3, ADRA2B | NFKB1 3941/4885BLM 3450/4885PMP22 1271/4885 |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | HTR2A, HTR2C, HTR3A | NFKB1 4835/4885BLM 3862/4885PMP22 475/4885 |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | HTR1D, HTR1A, HTR4 | NFKB1 4841/4885BLM 4452/4885PMP22 4304/4885 |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | HTR5A, HTR1A, HTR1D | NFKB1 4752/4885BLM 4529/4885PMP22 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.